{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:46Z","timestamp":1791464566978,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chest.2026.03.025","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:41:47Z","timestamp":1775306507000},"page":"1187-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET Molecular Imaging and Theranostics in Lung Diseases"],"prefix":"10.1016","volume":"170","author":[{"given":"Majid","family":"Assadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny D.","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Spillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser M.","family":"Rayyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Jarraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed A.","family":"Dweik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.chest.2026.03.025_bib1","first-page":"226","article-title":"Beyond fluorodeoxyglucose: molecular imaging of cancer in precision medicine","volume":"75","author":"Juweid","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.semnuclmed.2025.02.009","article-title":"PET\/MRI in non-small cell lung cancer (NSCLC)","volume":"55","author":"Alorfi","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.semnuclmed.2024.07.003","article-title":"Total-body PET\/CT: pros and cons","volume":"55","author":"Hicks","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.semnuclmed.2025.02.005","article-title":"Evolving paradigms in lung cancer: latest trends in diagnosis, management, and radiopharmaceuticals","volume":"55","author":"Cangut","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.chest.2026.03.025_bib5","article-title":"ImmunoPET: antibody-based PET imaging in solid tumors","volume":"9","author":"Manafi-Farid","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.chest.2026.03.025_bib6","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"(68)Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"16","key":"10.1016\/j.chest.2026.03.025_bib71","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.3390\/cancers13164101","article-title":"First Comparison between [18f]-FMISO and [18f]-faza for preoperative Pet imaging of hypoxia in lung cancer","volume":"13","author":"Thureau","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.chest.2026.03.025_bib43","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.semnuclmed.2024.09.008","article-title":"Current and future perspectives of PDL1 PET and SPECT imaging","volume":"54","author":"Dev","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"4","key":"10.1016\/j.chest.2026.03.025_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.chest.2026.03.025_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108574","article-title":"Transbronchial cryobiopsy in the era of precision thoracic diagnostics: histopathology, omics, radiomics, and AI converge","volume":"251","author":"Martella","year":"2026","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.chest.2026.03.025_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","article-title":"Enabling technologies for personalized and precision medicine","volume":"38","author":"Ho","year":"2020","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib10","first-page":"93","article-title":"Artificial intelligence in digital pathology diagnosis and analysis: technologies, challenges, and future prospects","volume":"12","author":"Zhang","year":"2026","journal-title":"Mil Med Res"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-021-02578-9","article-title":"The lungs were on fire: a pilot study of (18)F-FDG PET\/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease","volume":"23","author":"Liang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib12","first-page":"e17","article-title":"Exploring the potential value of [68 Ga]Ga-FAPI-46 PET\/CT for molecular assessment of fibroblast activation in interstitial lung disease: a single-center pilot study","volume":"50","author":"Bahtouee","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2967\/jnumed.121.261925","article-title":"Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study","volume":"63","author":"Rohrich","year":"2022","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.chest.2026.03.025_bib14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2967\/jnumed.124.268351","article-title":"Correlation of FAPI PET uptake with immunohistochemistry in explanted lungs from patients with advanced interstitial lung disease","volume":"65","author":"Hotta","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2026.03.025_bib16","article-title":"Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases - a systematic review","volume":"24","author":"Nielsen","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.chest.2026.03.025_bib17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.chest.2026.03.025_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923869","article-title":"Positron emission tomography to improve assessment of interstitial lung disease in patients with systemic sclerosis eligible for autologous stem cell transplantation","volume":"13","author":"Broens","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.chest.2026.03.025_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00259-023-06564-y","article-title":"Initial results with [(18)F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis","volume":"51","author":"Mori","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.00210414","article-title":"\u03b1v\u03b26 integrin may be a potential prognostic biomarker in interstitial lung disease","volume":"46","author":"Saini","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2026.03.025_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00259-019-04586-z","article-title":"Clinical quantification of the integrin \u03b1v\u03b26 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)","volume":"47","author":"Lukey","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 2","key":"10.1016\/j.chest.2026.03.025_bib22","doi-asserted-by":"crossref","first-page":"20s","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.chest.2026.03.025_bib23","doi-asserted-by":"crossref","DOI":"10.31083\/RCM37731","article-title":"Diagnostic performance of positron emission tomography in the assessment of systemic amyloidosis: a systematic review and meta-analysis","volume":"26","author":"Zhu","year":"2025","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01243894-200601000-00014","article-title":"PET scan in lung cancer: current recommendations and innovation","volume":"1","author":"Vansteenkiste","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"5 suppl","key":"10.1016\/j.chest.2026.03.025_bib25","doi-asserted-by":"crossref","first-page":"e93S","DOI":"10.1378\/chest.12-2351","article-title":"Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Gould","year":"2013","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2026.03.025_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014813","article-title":"The value of 18F-FDG PET\/CT in the diagnosis of different size of solitary pulmonary nodules","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.chest.2026.03.025_bib27","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s00259-022-05818-5","article-title":"Higher accuracy of [(68) Ga]Ga-DOTA-FAPI-04 PET\/CT comparing with 2-[(18)F]FDG PET\/CT in clinical staging of NSCLC","volume":"49","author":"Zhou","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.chest.2026.03.025_bib28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.123.267103","article-title":"Diagnostic potential of supplemental static and dynamic (68)Ga-FAPI-46 PET for primary (18)F-FDG-negative pulmonary lesions","volume":"65","author":"Rohrich","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1186\/s12885-024-13139-z","article-title":"Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor","volume":"24","author":"Son","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.chest.2026.03.025_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJM200007273430404","article-title":"Preoperative staging of non-small-cell lung cancer with positron-emission tomography","volume":"343","author":"Pieterman","year":"2000","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.chest.2026.03.025_bib31","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMoa022136","article-title":"Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography","volume":"348","author":"Lardinois","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2026.03.025_bib32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000678","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer","volume":"10","author":"Asamura","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.chest.2026.03.025_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7326\/0003-4819-139-11-200311180-00013","article-title":"Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis","volume":"139","author":"Gould","year":"2003","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.chest.2026.03.025_bib34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0000000000001607","article-title":"Comparison of 18 F-FDG PET\/CT and 68 Ga-FAPI-04 PET\/CT in patients with non-small cell lung cancer","volume":"43","author":"Can","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"5","key":"10.1016\/j.chest.2026.03.025_bib35","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.acra.2024.09.026","article-title":"Diagnostic Performance of FAPI PET\/CT for the detection of lymph node metastases in lung cancer patients: a meta-analysis","volume":"32","author":"Wan","year":"2025","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40644-024-00701-y","article-title":"[(18)F]FAPI adds value to [(18)F]FDG PET\/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Imaging"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semnuclmed.2025.02.011","article-title":"FAPI PET in the management of lung tumors","volume":"55","author":"Deleu","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.chest.2026.03.025_bib38","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1007\/s00330-023-10208-y","article-title":"Value of [(18)F]AlF-NOTA-FAPI-04 PET\/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [(18)F]FDG PET\/CT","volume":"34","author":"Qiao","year":"2024","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2214\/AJR.16.16532","article-title":"The value of FDG PET\/CT in treatment response assessment, follow-up, and surveillance of lung cancer","volume":"208","author":"Sheikhbahaei","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.chest.2026.03.025_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0284185113498536","article-title":"Diagnostic efficacy of PET and PET\/CT for recurrent lung cancer: a meta-analysis","volume":"55","author":"He","year":"2014","journal-title":"Acta Radiol"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib41","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.chest.2026.03.025_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.iotech.2020.03.001","article-title":"Molecular imaging for cancer immunotherapy","volume":"5","author":"Lim","year":"2020","journal-title":"Immunooncol Technol"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib44","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41467-023-38837-3","article-title":"Towards evidence-based response criteria for cancer immunotherapy","volume":"14","author":"Garralda","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.chest.2026.03.025_bib45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2214\/AJR.21.26538","article-title":"Imaging of cancer immunotherapy: response assessment methods, atypical response patterns, and immune-related adverse events, from the AJR special series on imaging of inflammation","volume":"218","author":"Sheikhbahaei","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.chest.2026.03.025_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tro-23-22","article-title":"Theranostics potential of somatostatin receptor scintigraphy in both small and non-small cell lung cancers: a preliminary study","volume":"7","author":"Bahtouee","year":"2023","journal-title":"Ther Radiol Oncol"},{"issue":"12","key":"10.1016\/j.chest.2026.03.025_bib47","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2967\/jnumed.123.266185","article-title":"Somatostatin receptor expression in lung neuroendocrine tumors: an analysis of DOTATATE PET scans","volume":"64","author":"Al-Toubah","year":"2023","journal-title":"J Nucl Med"},{"issue":"14","key":"10.1016\/j.chest.2026.03.025_bib48","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.7150\/thno.98819","article-title":"Theranostics with somatostatin receptor antagonists in SCLC: correlation of (68)Ga-SSO120 PET with immunohistochemistry and survival","volume":"14","author":"Mavroeidi","year":"2024","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.chest.2026.03.025_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1053\/j.semnuclmed.2024.05.001","article-title":"Radioligand therapy in patients with lung neuroendocrine tumors: a systematic review on efficacy and safety","volume":"54","author":"Malandrino","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"10","key":"10.1016\/j.chest.2026.03.025_bib50","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2967\/jnumed.123.265664","article-title":"(68)Ga-SSO-120 PET for initial staging of small cell lung cancer patients: a single-center retrospective study","volume":"64","author":"Kersting","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"10","key":"10.1016\/j.chest.2026.03.025_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014769","article-title":"The utility of 18F-FDG and 68Ga-DOTA-Peptide PET\/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.chest.2026.03.025_bib53","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers14051172","article-title":"Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals","volume":"14","author":"Fani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.chest.2026.03.025_bib54","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.chest.2026.03.025_bib55","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.cllc.2019.02.007","article-title":"Peptide receptor radionuclide therapy for patients with advanced lung carcinoids","volume":"20","author":"Naraev","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12885-025-13941-3","article-title":"A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)","volume":"25","author":"Capdevila","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.semnuclmed.2025.02.010","article-title":"Theranostics in lung neuroendocrine tumors","volume":"55","author":"Dev","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Kim","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.chest.2026.03.025_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.prp.2012.05.014","article-title":"Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung","volume":"208","author":"Tsuta","year":"2012","journal-title":"Pathol Res Pract"},{"issue":"7","key":"10.1016\/j.chest.2026.03.025_bib60","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1007\/s00259-025-07750-w","article-title":"Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions","volume":"53","author":"Virgolini","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.chest.2026.03.025_bib61","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","article-title":"[(68)Ga]Ga-Pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors' density by immunochemistry techniques","volume":"50","author":"Watts","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.chest.2026.03.025_bib62","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.chest.2026.03.025_bib63","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2967\/jnumed.110.075465","article-title":"PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine","volume":"51","author":"Watanabe","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.chest.2026.03.025_bib64","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A, Abdlkadir AS, Ruzzeh S, et al. [(177)Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review [published online ahead of print July 3, 2025]. Semin Nucl Med. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.06.010","DOI":"10.1053\/j.semnuclmed.2025.06.010"},{"key":"10.1016\/j.chest.2026.03.025_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2025.1737443","article-title":"Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors","volume":"5","author":"Wu","year":"2025","journal-title":"Front Nucl Med"},{"issue":"9","key":"10.1016\/j.chest.2026.03.025_bib66","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"suppl 1","key":"10.1016\/j.chest.2026.03.025_bib67","article-title":"FAP-targeted radiopharmaceutical therapy using 177Lu-, 90Y- and 225Ac-labeled 3BP-3940 in a cohort of 88 patients with 21 different advanced malignancies","volume":"66","author":"Zhang","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.chest.2026.03.025_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2967\/jnumed.124.268877","article-title":"Safety, biodistribution, and radiation dosimetry of the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with advanced medullary thyroid cancer and other neuroendocrine tumors","volume":"66","author":"von Guggenberg","year":"2025","journal-title":"J Nucl Med"},{"issue":"23","key":"10.1016\/j.chest.2026.03.025_bib69","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.7150\/thno.49480","article-title":"Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.chest.2026.03.025_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol Cancer"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226004344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226004344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:44:42Z","timestamp":1791463482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226004344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0012369226004344"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.03.025","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET Molecular Imaging and Theranostics in Lung Diseases","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}